Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)

Lihua H. Qiu

231 Xingangxi Road, 
Guangzhou, CN 
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
231 Xingangxi Road, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Lihua Qiu practices in Guangzhou, China. Qiu is rated as a Distinguished expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Cervical Dysplasia, Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Endoscopy.

Their clinical research consists of co-authoring 223 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 22 articles in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Locations

231 Xingangxi Road, Guangzhou, 510300, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
View 1 Less Clinical Trial

223 Total Publications

Perfluorooctanoic acid (PFOA) exposure induced ferroptosis through the PPARα/FABP7 signaling pathway in the liver of spotted sea bass (Lateolabrax maculatus).
Perfluorooctanoic acid (PFOA) exposure induced ferroptosis through the PPARα/FABP7 signaling pathway in the liver of spotted sea bass (Lateolabrax maculatus).
Journal: Fish & shellfish immunology
Published: August 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Qiu's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile